Inclusion body myositis: clinical features and pathogenesis

Area of Science:

• Neurology
• Immunology
• Genetics

Background:

• Inclusion body myositis (IBM) presents diagnostic and therapeutic challenges due to uncertain pathogenic mechanisms.
• Unique clinical (finger flexor/quadriceps weakness) and pathological (cytotoxic T cell invasion) features distinguish IBM.
• Historical focus on protein aggregates overshadowed autoimmune aspects, leading to debate on IBM's etiology.

Purpose of the Study:

• To review recent findings implicating autoimmunity in Inclusion body myositis.
• To consolidate evidence supporting a T cell-mediated autoimmune basis for IBM.
• To highlight potential therapeutic strategies targeting autoimmune mechanisms in IBM.

Main Methods:

• Review of recent immunological and genetic studies in IBM.
• Analysis of gene expression data revealing cytotoxic T cell signatures.
• Identification of clonal cytotoxic CD8+ T cells in muscle and blood.

Main Results:

• Identification of the autoantibody anti-cN1A in IBM patients.
• Genetic studies linked IBM to the common autoimmune MHC haplotype.
• Gene expression and cellular analyses confirmed a significant cytotoxic T cell response.
• Discovery of clonal, highly differentiated cytotoxic CD8+ T cells resistant to immunotherapy.

Conclusions:

• Growing evidence strongly supports Inclusion body myositis as an autoimmune T cell-mediated disease.
• The presence of specific autoantibodies and T cell signatures reinforces the autoimmune hypothesis.
• Targeting cytotoxic T cells offers a promising therapeutic avenue for IBM treatment.